An Open Label Phase I/II Study to Assess the Immunogenicity and Safety of a Single Prime-Boost Vaccination Schedule with a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy volunteers Aged 18 to 59 Years - Phase I/II Study of a H5N1 Vaccine

Baxter Innovations GmbH0 sites230 target enrollmentJanuary 26, 2009

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: H5N1 vaccination with a single Prime-Boost Vaccination schedule in healthy subjects aged 18 to 59 years.
Sponsor: Baxter Innovations GmbH
Enrollment: 230
Status: Active, not recruiting
Last Updated: 14 years ago

No summary available.

Registry

who.int

Start Date

January 26, 2009

End Date

TBD

Last Updated

14 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

•Male and female subjects will be eligible for participation in this study if they:
•Are 18 to 59 years of age, inclusive, on the day of screening;
•Have an understanding of the study and its procedures, agree to its provisions, and give written informed consent prior to study entry;
•Are generally healthy, as determined by the investigator’s clinical judgment through collection of medical history and performance of a physical examination.
•Are physically and mentally capable of participating in the study and follow its procedures;
•Agree to keep a daily record of symptoms for the duration of the study;
•If female of childbearing potential – have a negative urine pregnancy test result within 24 hours prior to the scheduled first vaccination and agree to employ adequate birth control measures for the duration of the study.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes

•Subjects will be excluded from participation in this study if they:
•Have a history of exposure to H5N1 virus or a history of vaccination with an H5N1 influenza vaccine;
•Are at high risk of contracting H5N1 influenza infection (e.g. poultry workers);
•Currently have or have a history of a significant neurological, cardiovascular, pulmonary (including asthma), hepatic, metabolic, rheumatic, autoimmune, hematological or renal disorders;
•Have any inherited or acquired immunodeficiency;
•Have a disease or are currently undergoing a form of treatment or were undergoing a form of treatment within 30 days prior to study entry that can be expected to influence immune response. Such treatment includes, but is not limited to, systemic or high dose inhaled (\>800µg/day of beclomethasone dipropionate or equivalent) corticosteroids, radiation treatment or other immunosuppressive or cytotoxic drugs;
•Have a history of severe allergic reactions or anaphylaxis;
•Have a rash, dermatological condition or tattoos which may interfere with injection site reaction rating;
•Have received any blood products or immunoglobulins within 90 days prior to study entry;
•Have donated blood or plasma within 30 days prior to study entry;